Sarcoidosis-associated Pulmonary Hypertension: Clinical Features and Outcomes in Arab Patients

Overview

Journal Ann Thorac Med

Specialty Pulmonary Medicine

Date 2010 Jun 29

PMID 20582173

Citations 16

Authors

Esam H Alhamad

Majdy M Idrees

Mohammed O Alanezi

Ahmad A AlBoukai

Shaffi Ahmad Shaik

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary hypertension (PH) occurs in many patients with interstitial lung disease, including sarcoidosis. We explored the frequency, clinical characteristics and outcomes of PH in Arab patients diagnosed with pulmonary sarcoidosis.

Methods: A retrospective study in three tertiary hospitals was performed on 96 patients who underwent Doppler echocardiography. Demographic and clinical characteristics, physiological studies and computed tomography (CT) results were collected, and compared between patients with and without PH.

Results: Twenty (20.8%) patients were found to have PH. Patients with PH were more likely to be symptomatic (cough, P = 0.008; dyspnea, P = 0.04), to have an advanced radiographic stage (P = 0.001), and to be receiving systemic therapy (P = 0.001), compared to those without PH. Physiological data including pulmonary function test parameters, arterial blood gas levels and oxygen saturation at rest and after exercise were all significantly lower in patients with PH compared to those without PH. Comparison of CT patterns between patients with and without PH showed significant differences in the frequencies of ground-glass opacity (61.5 vs. 28.8%, P = 0.032) and fibrosis (76.9 vs. 44.2%, P = 0.035). In total, four patients died during the study period, including three with evidence of PH.

Conclusions: The frequency of PH in the present study was 20.8%. Clinical, physiologic and radiographic characteristics appeared to differentiate patients with PH from those without PH. The presence of PH contributed to poor outcomes in patients with pulmonary sarcoidosis.

Citing Articles

Sarcoidosis-Associated Pulmonary Hypertension.

Israel-Biet D, Pastre J, Nunes H J Clin Med. 2024; 13(7).

PMID: 38610818 PMC: 11012707. DOI: 10.3390/jcm13072054.

Sarcoidosis Associated Pulmonary Hypertension.

Liu A, Price L, Sharma R, Wells A, Kouranos V Biomedicines. 2024; 12(1).

PMID: 38255282 PMC: 10813665. DOI: 10.3390/biomedicines12010177.

Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis.

Schimmelpennink M, Meek D, Vorselaars A, Langezaal L, van Moorsel C, van der Vis J Respir Res. 2022; 23(1):169.

PMID: 35752806 PMC: 9233403. DOI: 10.1186/s12931-022-02094-7.

WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.

Savale L, Huitema M, Shlobin O, Kouranos V, Nathan S, Nunes H Eur Respir Rev. 2022; 31(163).

PMID: 35140103 PMC: 9489049. DOI: 10.1183/16000617.0165-2021.

Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis.

Zhang S, Tong X, Zhang T, Wang D, Liu S, Wang L Front Cardiovasc Med. 2022; 8:809594.

PMID: 35111830 PMC: 8801498. DOI: 10.3389/fcvm.2021.809594.

References

Costabel U . Sarcoidosis: clinical update. Eur Respir J Suppl. 2002; 32:56s-68s. View

Baughman R, Sparkman B, Lower E . Six-minute walk test and health status assessment in sarcoidosis. Chest. 2007; 132(1):207-13. DOI: 10.1378/chest.06-2822. View

Lettieri C, Nathan S, Barnett S, Ahmad S, Shorr A . Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006; 129(3):746-52. DOI: 10.1378/chest.129.3.746. View

Wells A . High resolution computed tomography in sarcoidosis: a clinical perspective. Sarcoidosis Vasc Diffuse Lung Dis. 1998; 15(2):140-6. View

. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by.... Am J Respir Crit Care Med. 1999; 160(2):736-55. DOI: 10.1164/ajrccm.160.2.ats4-99. View

. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View

Remy-Jardin M, Giraud F, Remy J, Wattinne L, Wallaert B, Duhamel A . Pulmonary sarcoidosis: role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment. Radiology. 1994; 191(3):675-80. DOI: 10.1148/radiology.191.3.8184045. View

Chaouat A, Bugnet A, Kadaoui N, Schott R, Enache I, Ducolone A . Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172(2):189-94. DOI: 10.1164/rccm.200401-006OC. View

Samman Y, Ibrahim M, Wali S . Sarcoidosis in the western region of Saudi Arabia. Sarcoidosis Vasc Diffuse Lung Dis. 1999; 16(2):215-8. View

10.

Austin J, Muller N, Friedman P, Hansell D, Naidich D, Remy-Jardin M . Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleischner Society. Radiology. 1996; 200(2):327-31. DOI: 10.1148/radiology.200.2.8685321. View

11.

Nishimura K, Itoh H, Kitaichi M, NAGAI S, Izumi T . Pulmonary sarcoidosis: correlation of CT and histopathologic findings. Radiology. 1993; 189(1):105-9. DOI: 10.1148/radiology.189.1.8372178. View

12.

Scadding J . Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J. 1961; 2(5261):1165-72. PMC: 1970202. DOI: 10.1136/bmj.2.5261.1165. View

13.

Judson M, Baughman R, Teirstein A, Terrin M, Yeager Jr H . Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999; 16(1):75-86. View

14.

Bourbonnais J, Samavati L . Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008; 32(2):296-302. DOI: 10.1183/09031936.00175907. View

15.

Rodman D, Lindenfeld J . Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest. 1990; 97(2):500-2. DOI: 10.1378/chest.97.2.500. View

16.

Akira M, Kozuka T, Inoue Y, Sakatani M . Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest. 2005; 127(1):185-91. DOI: 10.1378/chest.127.1.185. View

17.

Spruit M, Thomeer M, Gosselink R, Troosters T, Kasran A, Debrock A . Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. 2004; 60(1):32-8. PMC: 1747159. DOI: 10.1136/thx.2004.022244. View

18.

Letizia C, Danese A, Reale M, Caliumi C, Delfini E, Subioli S . Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med. 2001; 43(4):257-61. View

19.

Khan J, Dossing M, von Sinner W, Bazarbashi M, Curley W . Sarcoidosis in native Saudis. Sarcoidosis. 1993; 10(1):50-5. View

20.

Handa T, Nagai S, Miki S, Fushimi Y, Ohta K, Mishima M . Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006; 129(5):1246-52. DOI: 10.1378/chest.129.5.1246. View